[go: up one dir, main page]

MX2019008961A - Composicion intranasal que comprende betahistina. - Google Patents

Composicion intranasal que comprende betahistina.

Info

Publication number
MX2019008961A
MX2019008961A MX2019008961A MX2019008961A MX2019008961A MX 2019008961 A MX2019008961 A MX 2019008961A MX 2019008961 A MX2019008961 A MX 2019008961A MX 2019008961 A MX2019008961 A MX 2019008961A MX 2019008961 A MX2019008961 A MX 2019008961A
Authority
MX
Mexico
Prior art keywords
betahistine
intranasal composition
intranasal
neurological
pharmaceutically acceptable
Prior art date
Application number
MX2019008961A
Other languages
English (en)
Other versions
MX381932B (es
Inventor
Meyer Thomas
John Wraight Chistopher
Original Assignee
Otolanum Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otolanum Ag filed Critical Otolanum Ag
Publication of MX2019008961A publication Critical patent/MX2019008961A/es
Publication of MX381932B publication Critical patent/MX381932B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente descripción se refiere a una composición farmacéutica que comprende, como sustancia activa, betahistina o una sal farmacéuticamente aceptable de esta, para su uso en el tratamiento de trastornos neurológicos u otológicos en un sujeto humano mediante aplicación intranasal.
MX2019008961A 2017-02-02 2018-02-02 Composicion intranasal que comprende betahistina. MX381932B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762453931P 2017-02-02 2017-02-02
PCT/EP2018/052695 WO2018141922A1 (en) 2017-02-02 2018-02-02 Intranasal composition comprising betahistine

Publications (2)

Publication Number Publication Date
MX2019008961A true MX2019008961A (es) 2019-10-15
MX381932B MX381932B (es) 2025-03-13

Family

ID=61187302

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019008961A MX381932B (es) 2017-02-02 2018-02-02 Composicion intranasal que comprende betahistina.

Country Status (33)

Country Link
US (2) US10456386B2 (es)
EP (2) EP3474850B1 (es)
JP (3) JP7714323B2 (es)
KR (1) KR102653545B1 (es)
CN (2) CN110418643A (es)
AR (1) AR111699A1 (es)
AU (1) AU2018216970B2 (es)
CA (1) CA3051725A1 (es)
CL (1) CL2019002145A1 (es)
CO (1) CO2019008657A2 (es)
DK (2) DK3698791T3 (es)
EA (1) EA201991817A1 (es)
ES (2) ES2969301T3 (es)
FI (1) FI3698791T3 (es)
HR (2) HRP20201137T1 (es)
HU (2) HUE065336T2 (es)
IL (1) IL268353B2 (es)
LT (2) LT3474850T (es)
MA (1) MA46778B1 (es)
MX (1) MX381932B (es)
MY (1) MY196333A (es)
NZ (1) NZ755931A (es)
PH (1) PH12019501785B1 (es)
PL (2) PL3474850T3 (es)
PT (2) PT3474850T (es)
RS (2) RS65099B1 (es)
SA (1) SA519402324B1 (es)
SG (1) SG11201906980YA (es)
SI (2) SI3698791T1 (es)
TN (1) TN2019000220A1 (es)
TW (1) TWI760429B (es)
WO (1) WO2018141922A1 (es)
ZA (1) ZA201904955B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018170532A1 (en) * 2017-03-22 2018-09-27 Franz, Lilian Ann Treatment method
CA3179806A1 (en) * 2020-04-14 2021-10-21 Glaxosmithkline Consumer Healthcare Holdings (Us) Llc Nasal spray formulation with moisturizing benefits
US20240165151A1 (en) * 2020-04-22 2024-05-23 Sanotize Research And Development Corp. Compositions and methods for treating upper respiratory infections

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2397840B1 (es) 1977-07-22 1981-03-20 Cherqui Jean
IT1229237B (it) * 1989-05-08 1991-07-26 Prodotti Formenti Sali di (2-(piridil)etil) metilammina
JPH03287535A (ja) * 1990-03-31 1991-12-18 Bairon Boeki Kk プラノプロフェン水溶液
JP3203056B2 (ja) * 1992-08-13 2001-08-27 株式会社ティ・ティ・エス技術研究所 メシル酸ベタヒスチンの経皮吸収製剤用組成物および経皮吸収製剤
US5897858A (en) * 1994-02-03 1999-04-27 Schering-Plough Healthcare Products, Inc. Nasal spray compositions exhibiting increased retention in the nasal cavity
JPH10139667A (ja) * 1996-11-15 1998-05-26 Yoshitomi Pharmaceut Ind Ltd 水性液剤
CA2446904A1 (en) 2001-05-24 2003-04-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
US7090830B2 (en) 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
JP3555598B2 (ja) 2001-06-27 2004-08-18 株式会社村田製作所 積層型インダクタ
JP2004196676A (ja) * 2002-12-16 2004-07-15 Rohto Pharmaceut Co Ltd 点鼻剤
JP4733333B2 (ja) * 2002-12-26 2011-07-27 ライオン株式会社 点鼻剤又は洗鼻剤
EP1530965B1 (en) 2003-11-11 2006-03-08 Mattern, Udo Controlled release delivery system of sexual hormones for nasal application
US7728015B2 (en) * 2004-04-22 2010-06-01 Mor Research Applications Ltd. Compositions for weight management
WO2005101979A2 (en) * 2004-04-22 2005-11-03 Mor Research Applications Ltd. Method of food intake management
AU2006202950A1 (en) * 2004-04-22 2006-10-19 Mor Research Applications Ltd. Methods and Compositions for Weight Management
EP2457580A1 (en) 2004-08-25 2012-05-30 The UAB Research Foundation Absorption enhancers for drug administration
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
JP2009504767A (ja) * 2005-08-17 2009-02-05 フレミング・アンド・カンパニー・ファーマシューティカルズ ビタミンｂ１２鼻用スプレーおよび使用方法
US8119668B2 (en) * 2005-12-23 2012-02-21 Nelson Erik B Treatment methods employing histamine H3 receptor antagonists, including betahistine
US8242148B2 (en) * 2005-12-23 2012-08-14 Nelson Erik B Treatment methods employing histamine H3 receptor antagonists, including betahistine
US20080066739A1 (en) 2006-09-20 2008-03-20 Lemahieu Edward Methods and systems of delivering medication via inhalation
US20090281156A1 (en) 2007-12-21 2009-11-12 Schering-Plough Healthcare Products, Inc, Enhancing photostabilization of oxymetazoline
RU2499592C2 (ru) * 2008-04-21 2013-11-27 Отономи, Инк. Фармацевтическая композиция для лечения ушных заболеваний
US8642631B2 (en) * 2008-05-27 2014-02-04 University Of Melbourne Methods of treating mammals with eustachian tube dysfunctions
CA2740087C (en) * 2008-10-08 2019-07-23 Kyphia Pharmaceuticals, Inc. Gaba conjugates and methods of use thereof
AU2015327762C1 (en) 2014-10-03 2020-10-22 Lachesis Biosciences Limited Intranasal compositions for treatment of neurological and neurodegenerative diseases and disorders

Also Published As

Publication number Publication date
HRP20231706T1 (hr) 2024-03-15
AR111699A1 (es) 2019-08-14
EP3474850B1 (en) 2020-04-22
KR102653545B1 (ko) 2024-04-04
ES2807798T3 (es) 2021-02-24
US20200022963A1 (en) 2020-01-23
JP2022051872A (ja) 2022-04-01
LT3698791T (lt) 2024-02-12
FI3698791T3 (fi) 2024-01-11
PT3474850T (pt) 2020-07-27
PL3698791T3 (pl) 2024-04-08
MY196333A (en) 2023-03-24
KR20190116341A (ko) 2019-10-14
IL268353B1 (en) 2023-06-01
TN2019000220A1 (en) 2021-01-07
IL268353B2 (en) 2023-10-01
CN118356397A (zh) 2024-07-19
PL3474850T3 (pl) 2020-09-21
ZA201904955B (en) 2021-05-26
CO2019008657A2 (es) 2020-01-17
HUE065336T2 (hu) 2024-05-28
PT3698791T (pt) 2024-01-12
PH12019501785B1 (en) 2024-02-28
JP2020506930A (ja) 2020-03-05
JP2024019731A (ja) 2024-02-09
RS60554B1 (sr) 2020-08-31
IL268353A (en) 2019-09-26
EA201991817A1 (ru) 2020-01-27
DK3474850T3 (da) 2020-08-03
RS65099B1 (sr) 2024-02-29
CN110418643A (zh) 2019-11-05
LT3474850T (lt) 2020-08-10
NZ755931A (en) 2022-07-29
AU2018216970B2 (en) 2023-12-21
HRP20201137T1 (hr) 2021-01-22
BR112019015687A2 (pt) 2020-04-28
WO2018141922A1 (en) 2018-08-09
US10456386B2 (en) 2019-10-29
MA46778A1 (fr) 2021-04-30
SA519402324B1 (ar) 2023-03-16
AU2018216970A1 (en) 2019-08-22
ES2969301T3 (es) 2024-05-17
MA46778B1 (fr) 2022-08-31
EP3698791A1 (en) 2020-08-26
DK3698791T3 (da) 2024-01-15
SI3474850T1 (sl) 2020-09-30
TW201831179A (zh) 2018-09-01
PH12019501785A1 (en) 2020-07-06
TWI760429B (zh) 2022-04-11
CA3051725A1 (en) 2018-08-09
EP3698791B1 (en) 2023-10-25
SG11201906980YA (en) 2019-08-27
EP3474850A1 (en) 2019-05-01
SI3698791T1 (sl) 2024-05-31
JP7714323B2 (ja) 2025-07-29
MX381932B (es) 2025-03-13
CL2019002145A1 (es) 2019-11-04
HUE050829T2 (hu) 2021-01-28
US20180214432A1 (en) 2018-08-02

Similar Documents

Publication Publication Date Title
SV2015005115A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
CO2021007993A2 (es) Compuestos de 2‐formil‐3‐hidroxifeniloximetilo capaces de modular la hemoglobina
CL2016001895A1 (es) Compuestos
CR20160222U (es) Formas solidas de acido { [ -(3- clorofenil) -3- hidroxipiridin -2-carbonil] amino} acetico, composiciones, y usos de las mismas
BR112017011972A2 (pt) derivados de azabicicloctano como agonistas de fxr para uso no tratamento de doenças hepáticas e gastrintestinais
PE20160052A1 (es) Composicion farmaceutica de clorhidrato de s-cetamina
MX2015003140A (es) Formulaciones de enzalutamida.
CO6821938A2 (es) Un compuesto de guanidina o una sal del mismo para el tratamiento de enfermedades relacionadas con vap -1
MX2018011785A (es) Derivados de indolina sustituidos como inhibidores de la replicacion viral del dengue.
UY37379A (es) Derivados de n-(piridin-2-il)piridina-sulfonamida y su uso en el tratamiento de enfermedades
CL2015002546A1 (es) Derivados 3-fenilpropilamina sustituidos para el tratamiento de enfermedades y trastornos oftálmicos
GT201600269A (es) Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble
UY37742A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
MX2017006113A (es) Nuevos profarmacos polimericos de la hormona del crecimiento humana (hgh).
CL2016002091A1 (es) Compuesto de triazina y su uso para fines medicinales
CL2015002835A1 (es) Nuevos derivados de piridina
PE20171243A1 (es) Composicion de liberacion modificada de orlistat y acarbosa para el tratamiento de la obesidad y trastornos metabolicos relacionados
CL2017000845A1 (es) Inhibidores de gingipaina de lisina
CA3010568A1 (en) Oromucosal nanofiber carriers for therapeutic treatment
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
CO2019011227A2 (es) N-ariletil-2-aminoquinolin-4-carboxamidas sustituidas y su uso
CO2019008657A2 (es) Composición intranasal que comprende betahistina
GT201700016A (es) [1,2,4] triazolo [4,3 -b] piridazinas para su uso en el tratamiento de enfermedades proliferativas
CL2016002321A1 (es) Compuestos derivados del ácido 2-8-5-cloropirimidin-2-ilamino-6,7,8,9-tetrahidro-5h-pirido3,2-bindol-5-ilacético, moduladores del receptor de prostaglandina d2 composición farmacéutica y su uso para el tratamiento de enfermedadestrastornos alérgicosinmunitarios.
CL2016001024A1 (es) Compuestos derivados de pirido[4,3-b]pirazin-2-carboxamidas; procedimiento de preparacion; composicion farmaceutica y uso para el tratamiento de trastornos neurodegenerativos, esquizofrenia, depresion, entre otras enfermedades.